Evidence map›Paper›PMID 16129845›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2005

Quality-of-life effects of prophylactic salpingo-oophorectomy versus gynecologic screening among women at increased risk of hereditary ovarian cancer.

Joanna B Madalinska, Judith Hollenstein, Eveline Bleiker, Marc van Beurden, Heiddis B Valdimarsdottir, Leon F Massuger, Katja N Gaarenstroom, Marian J E Mourits, René H M Verheijen, Eleonora B L van Dorst and 4 more

Registry-linked trialAbstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06497270 (A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery), which is not on this map. Cited by 77 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06497270 naactive not recruitingnot on this mapstarted 2024, after this paper: background citation

A 3D Bioprinted Hormone-producing Model for BRCA Mutated Patients After Risk Reducing Surgery: the DISC-OVARY Trial

TypeinterventionalSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCSRan2024 to 2027Enrolled3ConditionsBRCA Mutation, Estrogen Deficiency, Surgical Menopause, Menopause Related ConditionsArmsTheca and Granulosa Cell Isolation
3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Guideline
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Pharmacologically induced hypogonadism and sexual function in healthy young women and men.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2009
    Trial
  14. Article
  15. Article
  16. Contemporary risk assessment and risk-reducing strategies for tubo-ovarian cancer in women with BRCA pathogenic variants.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society · 2026
    Review
  17. Review
  18. Article
  19. Article
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Joanna B MadalinskaDivision of Psychosocial Research and Epidemiology, Department of Gynecology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Judith Hollenstein
Eveline Bleiker
Marc van Beurden
Heiddis B Valdimarsdottir
Leon F Massuger
Katja N Gaarenstroom
Marian J E Mourits
René H M Verheijen
Eleonora B L van Dorst
Hans van der Putten
Ko van der Velden
Henk Boonstra
Neil K Aaronson

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRecommendations for women at high risk of ovarian cancer include periodic gynecologic screening (GS) and prophylactic bilateral salpingo-oophorectomy (PBSO). The aim of the current study was to determine the quality-of-life (QOL) effects of PBSO versus GS. PATIENTS AND

methodsQuestionnaire data were obtained from 846 high-risk women who had participated in this nationwide, cross-sectional, observational study. Forty-four percent of the women had undergone PBSO, and 56% had opted for GS. Topics addressed by the questionnaire included generic QOL, cancer-specific distress, endocrine symptoms, and sexual functioning.

resultsNo statistically significant between-group differences were observed in generic QOL (Short Form-36), with women in both the PBSO and GS groups scoring similarly to the general population. Compared with GS, PBSO was associated with fewer breast and ovarian cancer worries (P < .001) and more favorable cancer risk perception (P < .05). However, the PBSO group reported significantly more endocrine symptoms (P < .001) and worse sexual functioning (P < .05) than the GS group. Eighty-six percent of women would choose PBSO again, and 63% would recommend it to a friend with familial risk of ovarian cancer.

conclusionPBSO had no measurable adverse impact on generic QOL of high-risk women. The favorable effects of PBSO in terms of reduced cancer worries and low perceived cancer risk need to be weighed against the increase in endocrine and sexual symptoms. Balanced information will help clinicians and high-risk women to make informed decisions about the optimal preventive health strategy.

Indexed as

Genetic Predisposition to DiseaseOvariectomyQuality of LifeAdultAgedAnxietyCross-Sectional StudiesDecision MakingFallopian TubesFemaleGenes, BRCA1Genes, BRCA2HumansMiddle AgedOvarian NeoplasmsRisk Assessment

Identifiers

PMID16129845

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.